Inhibition of p38 mitogen-activated protein kinase attenuates experimental autoimmune hepatitis: Involvement of nuclear factor kappa B

Figure 4 Effects of SB203580, a specific p38 MAPK inhibitor, on hepatic inflammation in EAH. A: Representative histology of control animals after standard induction of EAH showing portal inflammation (grade 2); B: Representative histology of animals treated with SB203580 after standard induction of EAH showing significantly reduced portal inflammation (grade 1); C: Average histological inflammation grade score for PBS, DMSO and SB203580 treated animals after standard induction of EAH (^aP < 0.05 between PBS and SB203580 treated animals); D: Serum alanine transaminase (ALT) levels in PBS, DMSO and SB203580 treated animals after standard induction of EAH (^aP < 0.05 between PBS and SB203580 treated animals).